Melanoma pp 213-237 | Cite as

Pediatric Melanoma and Atypical Melanocytic Neoplasms

  • Radhika Sreeraman Kumar
  • Jane L. Messina
  • Damon R. Reed
  • Vernon K. SondakEmail author


Melanoma is rare in children and presents with atypical features in comparison to adult melanoma. Adding to the diagnostic difficulty is the plethora of melanocytic neoplasms that are common in the pediatric population. It is often not possible to classify a lesion as unequivocally benign or melanoma, which pose challenges to the pathologist and treating physicians. This chapter focuses on the diagnosis and classification of atypical melanocytic neoplasms and melanoma in pediatric patients. Strategies for management of localized and advanced disease are reviewed including the role of sentinel lymph node biopsy, completion lymphadenectomy, adjuvant therapy and treatment of metastatic disease.


Pediatric melanoma Neonatal melanoma Congenital and dysplastic nevi Genetic syndromes Adolescent and young adult melanoma 


  1. 1.
    Mills OL, Marzban S, Zager JS, Sondak VK, Messina JL. Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. J Cutan Pathol. 2012;39(3):331–6.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Reed D, Kudchadkar R, Zager JS, Sondak VK, Messina JL. Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Cancer Netw. 2013;11(6):679–86.CrossRefGoogle Scholar
  3. 3.
    LaChance A, Shahriari M, Kerr PE, Grant-Kels JM. Melanoma: kids are not just little people. Clin Dermatol. 2016;34(6):742–8.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Austin MT, Xing Y, Hayes-Jordan AA, Lally KP, Cormier JN. Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States. J Pediatr Surg. 2013;48(11):2207–13.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Dean PH, Bucevska M, Strahlendorf C, Verchere C. Pediatric melanoma: a 35 year population-based review. Plast Reconstr Surg Glob Open. 2017;5(e1252):e1252.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Senerchia AA, Ribeiro KB, Rodriguez-Galindo C. Trends in incidence of primary cutaneous malignancies in children, adolescents, and young adults: a population-based study. Pediatr Blood Cancer. 2014;61(2):211–6.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Slade AD, Austin MT. Childhood melanoma: an increasingly important health problem in the USA. Curr Opin Pediatr. 2014;26(3):356–61.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Rajput A, Faizi SA, Nir I, Morris KT, Fahy B, Russell J, Wiggins C. Pediatric melanoma in New Mexico American Indians, Hispanics, and non-Hispanic whites, 1981–2009. Am J Surg. 2014;207(3):412–6.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk factor and survival analysis of the Surveillance, Epidemiology and End Results database. J Clin Oncol. 2005;23(21):4735–41.PubMedCrossRefGoogle Scholar
  11. 11.
    Averbook BJ, Lee SJ, Delman KA, Gow KW, Zager JS, Sondak VK, Messina JL, Sabel MS, Pittelkow MR, Ecker PM, Markovic SN, Swetter SM, Leachman SA, Testori A, Curiel-Lewandrowski C, Go RS, Jukic DM, Kirkwood JM. Pediatric melanoma: analysis of an international registry. Cancer. 2013;119(22):4012–9.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Perret-Court A, Fernandez C, Monestier S, Millet V, Tasei AM. Placental metastasis of melanoma: a new case and literature review. Ann Pathol. 2010;30(2):143–6.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Shuhaila A, Rohaizak M, Phang KS, Mahdy ZA. Maternal melanoma with placental metastasis. Singap Med J. 2008;49(3):e71–2.Google Scholar
  14. 14.
    Anderson JF, Kent S, Machin GA. Maternal malignant melanoma with placental metastasis: a case report with literature review. Pediatr Pathol. 1989;9(1):35–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Alexander A, Samlowski WE, Grossman D, Bruggers CS, Harris RM, Zone JJ, Noyes RD, Bowen GM, Leachman SA. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol. 2003;21(11):2179–86.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    De Carolis S, Garofalo S, Degennaro VA, Zannoni GF, Salvi S, Moresi S, Di Pasquo E, Scambia G. Placental and infant metastasis of maternal melanoma: a new case. J Obstet Gynaecol. 2015;35(4):417–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Richardson SK, Tannous ZS, Mihm MC Jr. Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma. J Am Acad Dermatol. 2002;47(1):77–90.PubMedCrossRefGoogle Scholar
  18. 18.
    Trumble ER, Smith RM, Pearl G, Wall J. Transplacental transmission of metastatic melanoma to the posterior fossa. Case report. J Neurosurg. 2005;103(2 Suppl):191–3.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Valenzano Menada M, Moioli M, Garaventa A, Nozza P, Foppiano M, Trimarchi N, Fulcheri E. Spontaneous regression of transplacental metastases from maternal melanoma in a newborn: case report and review of the literature. Melanoma Res. 2010;20(6):443–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Raso A, Mascelli S, Nozza P, Biassoni R, Negri F, Garaventa A, Tarantino V, Garre ML, Cama A, Capra V. Detection of transplacental melanoma metastasis using quantitative PCR. Diagn Mol Pathol. 2010;19(2):78–82.PubMedCrossRefGoogle Scholar
  21. 21.
    Tannous ZS, Mihm MC Jr, Sober AJ, Duncan LM. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol. 2005;52(2):197–203.PubMedCrossRefGoogle Scholar
  22. 22.
    Alikhan A, Ibrahimi OA, Eisen DB. Congenital melanocytic nevi: where are we now? Part I Clinical presentation, epidemiology, pathogenesis, histology, malignant transformation, and neurocutaneous melanosis. J Am Acad Dermatol. 2012;67(4):495.e1–17.CrossRefGoogle Scholar
  23. 23.
    Price HN, O’Haver J, Marghoob A, Badger K, Etchevers H, Krengel S. Practical application of the new classification scheme for congenital melanocytic nevi. Pediatr Dermatol. 2014;32(1):23–7.PubMedCrossRefGoogle Scholar
  24. 24.
    DeDavid M, Orlow SJ, Provost N, Marghoob AA, Rao BK, Huang CL, Wasti Q, Kopf AW, Bart RS. A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature. J Am Acad Dermatol. 1997;36(3 Pt 1):409–16.PubMedCrossRefGoogle Scholar
  25. 25.
    Krengel S, Hauschild A, Schafer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol. 2006;155(1):1–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Wramp ME, Langenbruch A, Augustin M, Zillikens D, Krengel S. Clinical course, treatment modalities, and quality of life in patients with congenital melanocytic nevi—data from the German CMN registry. J Dtsch Dermatol Ges. 2017;15(2):159–67.Google Scholar
  27. 27.
    Wood BA. Paediatric melanoma. Pathology. 2016;48(2):155–65. Scholar
  28. 28.
    Salgado CM, Basu D, Nikiforova M, Bauer BS, Johnson D, Rundell V, Grunwaldt LJ, Reyes-Mugica M. BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi. Pediatr Dev Pathol. 2015;18(1):1–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Phadke PA, Rakheja D, Le LP, Selim MA, Kapur P, Davis A, Mihm MC Jr, Hoang MP. Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases. Am J Surg Pathol. 2011;35(5):656–69.PubMedCrossRefGoogle Scholar
  30. 30.
    Charbel C, Fontaine RH, Malouf GG, Picard A, Kadlub N, El-Murr N, How-Kit A, Su X, Coulomb-L'Hermine A, Tost J, Mourah S, Aractingi S, Guegan S. NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J Invest Dermatol. 2014;134(4):1067–74.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Neuhold JC, Friesenhahn J, Gerdes N, Krengel S. Case reports of fatal or metastasizing melanoma in children and adolescents: a systemcatic analysis of the literature. Pediatr Dermatol. 2015;32(1):13–22.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Jain P, Kannan L, Kumar A, Sigamani E, Suri V, Basheer N, Suri A, Gulati S. Symptomatic neurocutaneous melanosis in a child. JAMA Neurol. 2013;70(4):516.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Ruiz-Maldonado R, Tamayo L, Laterza AM, Duran C. Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pediatr. 1992;120(6):906–11.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Kadonaga JN, Frieden IJ. Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol. 1991;24 ((5):747–55.CrossRefGoogle Scholar
  35. 35.
    Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, Hing S, Chalker J, McKenzie K, Abu-Amero S, Slater O, Chanudet E, Palmer R, Morrogh D, Stanier P, Healy E, Sebire NJ, Moore GE. Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol. 2013;133(9):2229–36.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Pawlikowski JS, Brock C, Chen SC, Al-Olabi L, Nixon C, McGregor F, Paine S, Chanudet E, Lambie W, Holmes WM, Mullin JM, Richmond A, Wu H, Blyth K, King A, Kinsler VA, Adams PD. Acute inhibition of MEK suppresses congenital melanocytic nevus syndrome in a murine model driven by activated NRAS and Wnt signaling. J Invest Dermatol. 2015;135(8):2093–101.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Kinsler VA, O'Hare P, Jacques T, Hargrave D, Slater O. MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children. Br J Cancer. 2017;116(8):990–3.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Asai J, Takenaka H, Ikada S, Soga F, Kishimoto S. Congenital malignant melanoma: a case report. Br J Dermatol. 2004;151(3):693–7.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Su A, Low L, Li X, Zhou S, Mascarenhas L, Barnhill RL. De novo congenital melanoma: analysis of 2 cases with array comparative genomic hybridization. Am J Dermatopathol. 2014;36(11):915–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Lange JR, Pallis BE, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Database. J Clin Oncol. 2007;25(11):1363–8.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Aldrink JH, Selim MA, Diesen DL, Johnson J, Pruitt SK, Tyler DS, Seigler HF. Pediatric melanoma: a single-institution experience of 150 patients. J Pediatr Surg. 2009;44(8):4–21.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Downard CD, Rapkin LB, Gow KW. Melanoma in children and adolescents. Surg Oncol. 2007;16(3):215–20.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Livestro DP, Kaine EM, Michaelson JS, Mihm MC, Haluska FG, Muzikansky A, Sober AJ, Tanabe KK. Melanoma in the young: differences and similarities with adult melanoma. A case-matched controlled analysis. Cancer. 2007;110(3):614–24.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Paradela S, Fonseca E, Pita-Fernandez S, Kantrow SM, Diwan AH, Herzog C, Prieto VG. Prognostic factors for melanoma in children and adolescents: a clinicopathologic, single-center study of 137 patients. Cancer. 2010;116(18):4334–44.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Pappo AS. Melanoma in children and adolescents. Eur J Cancer. 2003;39(18):2651–61.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Dika E, Ravaioli GM, Fanti PA, Neri I, Patrizi A. Spitz nevi and other spitzoid neoplasms in children: overview of incidence data and diagnostic criteria. Pediatr Dermatol. 2017;34(1):25–32.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Latchana N, Regan K, Howard JH, Aldrink JH, Ranalli MA, Peters SB, Zhang X, Gru A, Payne PR, Suarez-Kelly LP, Carson WE 3rd. Global microRNA profiling for diagnostic appraisal of melanocytic Spitz tumors. J Surg Res. 2016;205(2):350–8.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, Oh KS, Imoto K, Inui H, Moriwaki S, Emmert S, Pike KM, Raziuddin A, Plona TM, DiGiovanna JJ, Tucker MA, Kraemer KH. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet. 2011;48(3):168–76.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Bis S, Tsao H. Melanoma genetics: the other side. Clin Dermatol. 2013;31(2):148–55.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Berg P, Wennberg AM, Tuominen R, Sander B, Rozell BL, Platz A, Hansson J. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res. 2004;14(4):251–5.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Navid F. Genetic alterations in childhood melanoma. Am Soc Clin Oncol Educ Book. 2012, 2012:589–92.Google Scholar
  52. 52.
    Wong JR, Harris JK, Rodriguez-Galindo C, Johnson KJ. Incidence of childhood and adolescent melanoma in the United States: 1973–2009. Pediatrics. 2013;131(5):846–54.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Ferrari A, Bono A, Baldi M, Collini P, Casanova M, Pennacchioli E, Terenziani M, Marcon I, Santinami M, Bartoli C. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics. 2005;115(3):649–54.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Lewis KG. Trends in pediatric melanoma mortality in the United States, 1968 through 2004. Dermatol Surg. 2008;34(2):152–9.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Neier M, Pappo A, Navid F. Management of melanomas in children and young adults. J Pediatr Hematol Oncol. 2012;34(Suppl 2):S51–4.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Han D, Zager JS, Han G, Marzban SS, Puleo CA, Sarnaik AA, Reed D, Messina JL, Sondak VK. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol. 2012;19(12):3888–95.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Cordoro KM, Gupta D, Frieden IJ, McCalmont T, Kashani-Sabet M. Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children. J Am Acad Dermatol. 2013;68(6):913–25.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Mitkov M, Chrest M, Diehl NN, Heckman MG, Tollefson M, Jambusaria-Pahlajani A. Pediatric melanomas often mimic benign skin lesions: a retrospective study. J Am Acad Dermatol. 2016;75(4):706–11.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Gerami P, Busam K, Cochran A, Cook MG, Duncan LM, Elder DE, Fullen DR, Guitart J, LeBoit PE, Mihm MC Jr, Prieto VG, Rabkin MS, Scolyer RA, Xu X, Yun SJ, Obregon R, Yazdan P, Cooper C, Weitner BB, Rademaker A, Barnhill RL. Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. Am J Surg Pathol. 2014;38(7):934–40.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Tang W, David FB, Wilson MM, Barwick BG, Leyland-Jones BR, Bouzyk MM. DNA extraction from formalin-fixed, paraffin-embedded tissue. Cold Spring Harb Protoc. 2009;2009(2):pdb.prot5138.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Thirlwell C, Eymard M, Feber A, Teschendorff A, Pearce K, Lechner M, Widschwendter M, Beck S. Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. Methods. 2010;52(3):248–54.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, Lipson D, Otto G, Brennan K, Murali R, Garrido M, Miller VA, Ross JS, Berger MF, Sparatta A, Palmedo G, Cerroni L, Busam KJ, Kutzner H, Cronin MT, Stephens PJ, Bastian BC. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    DeMarchis EH, Swetter SM, Jennings CD, Kim J. Fluorescence in situ hybridization analysis of atypical melanocytic proliferations and melanoma in young patients. Pediatr Dermatol. 2014;31(5):561–9.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30(2):117–22.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Casper DJ, Ross KI, Messina JL, Sondak VK, Bodden CN, McCardle TW, Glass LF. Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathol. 2010;32(7):650–4.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    McNutt NS, Urmacher C, Hakimian J, Hoss DM, Lugo J. Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity. J Cutan Pathol. 1995;22(6):502–17.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Conway C, Beswick S, Elliott F, Chang YM, Randerson-Moor J, Harland M, Affleck P, Marsden J, Sanders DS, Boon A, Knowles MA, Bishop DT, Newton-Bishop JA. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer. 2010;49(5):425–38.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Yazdan P, Cooper C, Sholl LM, Busam K, Rademaker A, Weitner BB, Obregon R, Guitart J, Gerami P. Comparative analysis of atypical spitz tumors with heterozygous versus homozygous 9p21 deletions for clinical outcomes, histomorphology, BRAF mutation, and p16 expression. Am J Surg Pathol. 2014;38(5):638–45.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Mason A, Wititsuwannakul J, Klump VR, Lott J, Lazova R. Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma. J Cutan Pathol. 2012;39(12):1062–74.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rutten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43(10):1018–21.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    McCormack CJ, Conyers RK, Scolyer RA, Kirkwood J, Speakman D, Wong N, Kelly JW, Henderson MA. Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy. Melanoma Res. 2014;24(5):437–47.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Grignol V, Fairchild ET, Zimmerer JM, Lesinski GB, Walker MJ, Magro CM, Kacher JE, Karpa VI, Clark J, Nuovo G, Lehman A, Volinia S, Agnese DM, Croce CM, Carson WE 3rd. miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions. Br J Cancer. 2011;105(7):1023–9.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Latchana N, Martin del Campo S, Grignol V, Carson M, Clark J, Peters S, Carson III W. Classifications of indeterminate melanomas by microRNA profiling. In: Perspectives in melanoma XVIII, Dublin, Ireland, September 19, 2014.Google Scholar
  74. 74.
    Minca EC, Al-Rohil RN, Wang M, Harms PW, Ko JS, Collie AM, Kovalyshyn I, Prieto VG, Tetzlaff MT, Billings SD, Andea AA. Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions. Mod Pathol. 2016;29(8):832–43.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Cerrato F, Wallins JS, Webb ML, McCarty ER, Schmidt BA, Labow BI. Outcomes in pediatric atypical Spitz tumors treated without sentinel lymph node biopsy. Pediatr Dermatol. 2012;29(4):448–53.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Rand AJ, Flejter WL, Dowling CA, Brooke LM, Boland GM, Kroshinsky D, Rosenblum IR, Herandez-Perez M, Reimann JDR. Atypical ALK-positive Spitz tumors with 9p21 homozygous deletion: report of two cases and review of the literature. J Cutan Pathol. 2018;45(2):136–40.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Gerami P, Cooper C, Bajaj S, Wagner A, Fullen D, Busam K, Scolyer RA, Xu X, Elder DE, Abraham RM, Prieto VG, Guitart J, Liu P, Pestova E, Barnhill RL. Outcomes of atypical Spitz tumors with chromosomal copy number aberrations and conventional melanomas in children. Am J Surg Pathol. 2013;37(9):1387–94.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Moscarella E, Zalaudek I, Cerroni L, Sperduti I, Catricala C, Smolle J, Hofmann-Wellenhof R, Sgambato A, Pellacani G, Argenziano G. Excised melanocytic lesions in children and adolescents: a 10-year survey. Br J Dermatol. 2012;167(2):368–73.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Barnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, ‘Spitzoid melanoma’ and risk assessment. Mod Pathol. 2006;19(Suppl 2):S21–33.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Spatz A, Calonje E, Handfield-Jones S, Barnhill RL. Spitz tumors in children: a grading system for risk stratification. Arch Dermatol. 1999;135(3):282–5.PubMedCrossRefGoogle Scholar
  81. 81.
    Zaal LH, Mooi WJ, Klip H, van der Horst CM. Risk of malignant transformation of congenital melanocytic nevi: a retrospective nationwide study from The Netherlands. Plast Reconstr Surg. 2005;116(7):1902–9.PubMedCrossRefGoogle Scholar
  82. 82.
    North JP, Garrido MC, Kolaitis NA, LeBoit PE, McCalmont TH, Bastian BC. Fluorescence in situ hybridization as an ancillary tool in the diagnosis of ambiguous melanocytic neoplasms: a review of 804 cases. Am J Surg Pathol. 2014;38(6):824–31.PubMedCrossRefGoogle Scholar
  83. 83.
    Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003;163(5):1765–70.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Yeh I, Mully TW, Wiesner T, Vemula SS, Mirza SA, Sparatta AJ, McCalmont TH, Bastian BC, LeBoit PE. Ambiguous melanocytic tumors with loss of 3p21. Am J Surg Pathol. 2014;38(8):1088–95.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Botton T, Yeh I, Bastian BC. Melanoma BRAF fusions (Letter). Clin Cancer Res. 2014;20(24):6631.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Amin SM, Haugh AM, Lee CY, Zhang B, Bubley JA, Merkel EA, Verzi AE, Gerami P. A Comparison of morphologic and molecular features of BRAF, ALK, and NTRK1 fusion spitzoid neoplasms. Am J Surg Pathol. 2017;41(4):491–8.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Kiuru M, Jungbluth A, Kutzner H, Wiesner T, Busam KJ. Spitz tumors: comparison of histological features in relationship to immunohistochemical staining for ALK and NTRK1. Int J Surg Pathol. 2016;24(3):200–6.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Wiesner T, Kutzner H, Cerroni L, Mihm MC Jr, Busam KJ, Murali R. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. Pathology. 2016;48(2):113–31.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Lee CY, Sholl LM, Zhang B, Merkel EA, Amin SM, Guitart J, Gerami P. Atypical Spitzoid neoplasms in childhood: a molecular and outcome study. Am J Dermatopathol. 2017;39(3):181–6.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Gerami P, Jewell SS, Morrison LE, Blondin B, Schulz J, Ruffalo T, Matushek P 4th, Legator M, Jacobson K, Dalton SR, Charzan S, Kolaitis NA, Guitart J, Lertsbarapa T, Boone S, LeBoit PE, Bastian BC. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol. 2009;33(8):1146–56.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Busam KJ, Shah KN, Gerami P, Sitzman T, Jungbluth AA, Kinsler V. Reduced H3K27me3 expression is common in nodular melanomas of childhood associated with congenital melanocytic nevi but not in proliferative nodules. Am J Surg Pathol. 2017;41(3):396–404.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Bahrami AE, Easton J, Mulder H, Lee S, Barnhill R, Pappo AS. Analysis of TERT promoter mutations in pediatric melanoma. J Clin Oncol. 2014;32(5s Suppl):abstr 9023.Google Scholar
  93. 93.
    Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A. TERT promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Sci Rep. 2015;5:11200.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Seynnaeve B, Lee S, Borah S, Park Y, Pappo A, Kirkwood JM, Bahrami A. Genetic and epigenetic alterations of TERT are associated with inferior outcome in adolescent and young adult patients with melanoma. Sci Rep. 2017;7:45704.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Lallas A, Kyrgidis A, Ferrara G, Kittler H, Apalla Z, Castagnetti F, Longo C, Moscarella E, Piana S, Zalaudek I, Argenziano G. Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. Lancet Oncol. 2014;15(4):e178–83.PubMedCrossRefGoogle Scholar
  96. 96.
    Zhao G, Lee KC, Peacock S, Reisch LM, Knezevich SR, Elder DE, Piepkorn MW, Elmore JG, Barnhill RL. The utilization of spitz-related nomenclature in the histological interpretation of cutaneous melanocytic lesions by practicing pathologists: results from the M-Path study. J Cutan Pathol. 2017;44(1):5–14.PubMedCrossRefGoogle Scholar
  97. 97.
    Lee KC, Peacock S, Weinstock MA, Zhao GA, Knezevich SR, Elder DE, Barnhill RL, Piepkorn MW, Reisch LM, Carney PA, Onega T, Lott JP, Elmore JG. Variation among pathologists’ treatment suggestions for melanocytic lesions: a survey of pathologists. J Am Acad Dermatol. 2017;76(1):121–8.PubMedCrossRefGoogle Scholar
  98. 98.
    D’Orsi CJ, Bassett LW, Geig SA, Jackson VP, Kopans DB, Linver MN, et al. ACR BI-RADS mammography. In: ACR breast imaging reporting and data system, Breast Imaging Atlas. 4th ed. 2003. p. 193–8.Google Scholar
  99. 99.
    Piepkorn MW, Barnhill RL, Elder DE, Knezevich SR, Carney PA, Reisch LM, Elmore JG. The MPATH-Dx reporting schema for melanocytic proliferations and melanoma. J Am Acad Dermatol. 2014;70(1):131–41.PubMedCrossRefGoogle Scholar
  100. 100.
    Sondak VK, Messina JL. Unusual presentations of melanoma: melanoma of unknown primary site, melanoma arising in childhood, and melanoma arising in the eye and on mucosal surfaces. Surg Clin North Am. 2014;94(5):1059–73.PubMedCrossRefGoogle Scholar
  101. 101.
    Sreeraman Kumar R, Messina JL, Reed D, Navid F, Sondak VK. Pediatric melanoma and atypical melanocytic neoplasms. Cancer Treat Res. 2016;167:331–69.PubMedCrossRefGoogle Scholar
  102. 102.
    Lallas A, Apalla Z, Ioannides D, Lazaridou E, Kyrgidi A, Broganelli P, Alfano R, Zalaudek I, Argenziano G. Update on dermoscopy of Spitz/Reed naevi and management guidelines by the International Dermoscopy Society. Br J Dermatol. 2017;177(3):645–55. Scholar
  103. 103.
    Urso C. A new perspective for Spitz tumors? Am J Dermatopathol. 2005;27(4):364–6.PubMedCrossRefGoogle Scholar
  104. 104.
    Barnhill RL, Argenyi Z, Berwick M, Duray PH, Erickson L, Guitart J, Horenstein MG, Lowe L, Messina J, Paine S, Piepkorn MW, Prieto V, Rabkin MS, Schmidt B, Selim A, Shea CR, Trotter MJ. Atypical cellular blue nevi (cellular blue nevi with atypical features): lack of consensus for diagnosis and distinction from cellular blue nevi and malignant melanoma (“malignant blue nevus”). Am J Surg Pathol. 2008;32(1):36–44.PubMedCrossRefGoogle Scholar
  105. 105.
    Miglioretti DL, Johnson E, Williams A, Greenlee RT, Weinmann S, Solberg LI, Feigelson HS, Roblin D, Flynn MJ, Vanneman N, Smith-Bindman R. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr. 2013;167(8):700–7.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Howe NL, Ronckers CM, Rajaraman P, Sir Craft AW, Parker L, Berrington de Gonzalez A. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380(9840):499–505.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Gatidis S, Schmidt H, Gucke B, Bezrukov I, Seitz G, Ebinger M, Reimold M, Pfannenberg CA, Nikolaou K, Schwenzer NF, Schafer JF. Comprehensive oncologic imaging in infants and preschool children with substantially reduced radiation exposure using combined simultaneous (1)(8) F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging: a direct comparison to (1)(8) F-fluorodeoxyglucose positron emission tomography/computed tomography. Investig Radiol. 2016;51(1):7–14.CrossRefGoogle Scholar
  108. 108.
    Freemyer B, Hamilton E, Warneke CL, Ali AM, Herzog C, Hayes-Jordan A, Austin M. Treatment outcomes in pediatric melanoma - Are there benefits to specialized care? J Pediatr Surg. 2016;51(12):2063–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Lorimer PD, White RL, Walsh K, Han Y, Kirks RC, Symanowski J, Forster MR, Sarantou T, Salo JC, Hill JS. Pediatric and adolescent melanoma: a National Cancer Data Base update. Ann Surg Oncol. 2016;23(12):4058–66.PubMedCrossRefGoogle Scholar
  110. 110.
    Wong JY, Sondak VK. Unanswered questions about margin recommendations for primary cutaneous melanoma. J Natl Compr Cancer Netw. 2012;10(3):357–65.CrossRefGoogle Scholar
  111. 111.
    Howman-Giles R, Shaw HM, Scolyer RA, Murali R, Wilmott J, McCarthy SW, Uren RF, Thompson JF. Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients. Ann Surg Oncol. 2010;17(1):138–43.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Howman-Giles R, Shaw HM, Scolyer RA, Murali R, Wilmott J, McCarthy SW, Uren RF, Thompson JF. Sentinel lymph node biopsy in pediatric and adolescent patients: a proven technique. J Surg Oncol. 2012;104(4):405–19.Google Scholar
  113. 113.
    Stanelle EJ, Busam KJ, Rich BS, Christison-Lagay ER, Dunkel IJ, Marghoob AA, Halpern A, Coit DG, La Quaglia MP. Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis. J Pediatr Surg. 2015;50(6):1019–23.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Brecht IB, Garbe C, Gefeller O, Pfahlberg A, Bauer J, Eigentler TK, Offenmueller S, Schneider DT, Leiter U. 443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. Eur J Cancer. 2015;51(7):861–8.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Han D, Turner L, Reed D, Messina JL, Sondak VK. The prognostic significance of lymph node metastasis in pediatric melanoma and atypical melanocytic proliferations. Expert Rev Dermatol. 2013b;8(2):103–6.CrossRefGoogle Scholar
  116. 116.
    Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E, Kraybill WG, McKinnon JG, Wang HJ, Elashoff R, Faries MB. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Palmer PE 3rd, Warneke CL, Hayes-Jordan AA, Herzog CE, Hughes DP, Lally KP, Austin MT. Complications in the surgical treatment of pediatric melanoma. J Pediatr Surg. 2013;48(6):1249–53.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013a;31(35):4387–93.PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Coit DG, Ernstoff MS, Busam KJ. Is pediatric melanoma always malignant? Cancer. 2013;119(22):3910–3.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Harms KL, Lowe L, Fullen DR, Harms PW. Atypical Spitz tumors: a diagnostic challenge. Arch Pathol Lab Med. 2015;139(10):1263–70.PubMedCrossRefGoogle Scholar
  121. 121.
    Ludgate MW, Fullen DR, Lee J, Lowe L, Bradford C, Geiger J, Schwartz J, Johnson TM. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer. 2009;115(3):631–41.PubMedCrossRefGoogle Scholar
  122. 122.
    Barnhill RL, Argenyi ZB, From L, Glass LF, Maize JC, Mihm MC Jr, Rabkin MS, Ronan SG, White WL, Piepkorn M. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol. 1999;30(5):513–20.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, Cormier JN, Gorman M, Kim TY, McMasters KM, Noyes RD, Schuchter LM, Valsecchi ME, Weaver DL, Lyman GH. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30(23):2912–8.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Rossi CR, De Salvo GL, Bonandini E, Mocellin S, Foletto M, Pasquali S, Pilati P, Lise M, Nitti D, Rizzo E, Montesco MC. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol. 2008;15(4):1202–10.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    McMasters KM, Wong SL, Edwards MJ, Chao C, Ross MI, Noyes RD, Viar V, Cerrito PB, Reintgen DS. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2002;9(2):137–41.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Murali R, Desilva C, Thompson JF, Scolyer RA. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28(29):4441–9.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Urso C, Borgognoni L, Doria M, Tinacci G, Zini E. Non-sentinel lymph node involvement in a patient with an atypical Spitz tumor and a positive sentinel node. Report of a case and review of the literature. J Cutan Pathol. 2009;36(5):586–90.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Faries MB, Thompson JF, Cochran A, Elashoff R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang HJ, Morton DL, Group MC. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol. 2010;17(12):3324–9.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Sarnaik AA, Puleo CA, Zager JS, Sondak VK. Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control. 2009;16(3):240–7.CrossRefPubMedGoogle Scholar
  130. 130.
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Chao MM, Schwartz JL, Wechsler DS, Thornburg CD, Griffith KA, Williams JA. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer. 2005;44(5):441–8.PubMedCrossRefPubMedCentralGoogle Scholar
  132. 132.
    Navid F, Furman WL, Fleming M, Rao BN, Kovach S, Billups CA, Cain AM, Amonette R, Jenkins JJ, Pappo AS. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer. 2005;103(4):780–7.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Shah NC, Gerstle JT, Stuart M, Winter C, Pappo A. Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: the Hospital for Sick Children experience. J Pediatr Hematol Oncol. 2006;28(8):496–500.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U, Group EM. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633):117–26.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Sales F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012;48(2):218–25.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Herndon TM, Demko SG, Jiang X, He K, Gootenberg JE, Cohen MH, Keegan P, Pazdur R. US Food and Drug Administration approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. Oncologist. 2012;17(10):1323–8.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon alpha-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol. 2011;67(3):657–66.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Sykes A, Davidoff AM, Shulkin BL, Bahrami A, Furman WL, Mao S, Wu J, Schiff D, Rao B, Pappo A. Feasibility of pegylated interferon in children and young adults with resected high-risk melanoma. Pediatr Blood Cancer. 2016;63(7):1207–13.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Moon J, Ribas A, Kirkwood JM, Sondak VK. Southwest Oncology Group S0008: a phase III trial of high-dose interferon alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma—an intergroup study of Cancer And Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014;32(33):3771–8.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de Pril V, de Schaetzen G, Suciu S, Testori A. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A. Pembrolizumab versus ipilimumab in advanced melanoma. New Eng J Med. 2015;372(26):2521–32.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob J, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA. Adjuvant nivolumab versus ipilimumab in resected Stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.Google Scholar
  143. 143.
    Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res. 2012;18(12):3242–9.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Lu C, Zhang J, Nagahawatte P, Easton J, Lee S, Liu Z, Ding L, Wyczalkowski MA, Valentine M, Navid F, Mulder H, Tatevossian RG, Dalton J, Davenport J, Yin Z, Edmonson M, Rusch M, Wu G, Li Y, Parker M, Hedlund E, Shurtleff S, Raimondi S, Bhavin V, Donald Y, Mardis ER, Wilson RK, Evans WE, Ellison DW, Pounds S, Dyer M, Downing JR, Pappo A, Bahrami A. The genomic landscape of childhood and adolescent melanoma. J Invest Dermatol. 2015;135(3):816–23.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R, Wolchok JD, Streicher H, Mackall CL. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22(6):1364–70.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Bristol-Myers Squibb. U.S. Food and Drug Administration expands approval of Yervoy (ipilimumab) to include pediatric patients 12 years and older with unresectable or metastatic melanoma. Bristol-Myers Squibb online press release July 24, 2017.
  147. 147.
    Weyand AC, Mody RJ, Rabah RM, Opipari VP. PD-1 inhibition in congenital pigment synthesizing metastatic melanoma. Pediatr Blood Cancer. 2017;65(1):e26702.CrossRefGoogle Scholar
  148. 148.
    Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011;6:34.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Weintraub D, Yen CP, Xu Z, Savage J, Williams B, Sheehan J. Gamma knife surgery of pediatric gliomas. J Neurosurg Pediatr. 2012;10(6):471–7.PubMedCrossRefPubMedCentralGoogle Scholar
  150. 150.
    Ferrari A, Bisogno G, Cecchetto G, Santinami M, Maurichi A, Bono A, Vajna De Pava M, Pierani P, Bertolini P, Rossi CR, De Salvo GL. Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience. J Pediatr. 2014;164(2):376–82.e1–2.CrossRefGoogle Scholar
  151. 151.
    Georgina V. Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, Ran Ji, Pingkuan Zhang, Bijoyesh Mookerjee, Jeff Legos, Richard Kefford, Reinhard Dummer, John M. Kirkwood. Adjuvant Dabrafenib plus Trametinib in Stage III -Mutated Melanoma. N Engl J Med. 2017;377(19):1813–1823.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, Alexandre Reuben, Miles C Andrews, Merrick I Ross, Isabella C Glitza, Janice Cormier, Wen-Jen Hwu, Hussein A Tawbi, Sapna P Patel, Jeffrey E Lee, Jeffrey E Gershenwald, Christine N Spencer, Vancheswaran Gopalakrishnan, Roland Bassett, Lauren Simpson, Rosalind Mouton, Courtney W Hudgens, Li Zhao, Haifeng Zhu, Zachary A Cooper, Khalida Wani, Alexander Lazar, Patrick Hwu, Adi Diab, Michael K Wong, Jennifer L McQuade, Richard Royal, Anthony Lucci, Elizabeth M Burton, Sangeetha Reddy, Padmanee Sharma, James Allison, Phillip A Futreal, Scott E Woodman, Michael A Davies, Jennifer A Wargo. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. The Lancet Oncol. 2018;19(2):181–193.Google Scholar
  153. 153.
    Francisco Bautista, Angelo Paci, Veronique Minard-Colin, Christelle Dufour, Jacques Grill, Ludovic Lacroix, Pascale Varlet, Dominique Valteau-Couanet, Birgit Geoerger. Vemurafenib in pediatric patients with mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61(6):1101–1103.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Radhika Sreeraman Kumar
    • 1
  • Jane L. Messina
    • 2
    • 3
  • Damon R. Reed
    • 4
    • 5
  • Vernon K. Sondak
    • 6
    • 7
    Email author
  1. 1.Radiation Oncology ServicesRiverdaleUSA
  2. 2.Departments of Anatomic Pathology and Cutaneous OncologyMoffitt Cancer CenterTampaUSA
  3. 3.Departments of Pathology and Cell Biology and DermatologyUniversity of South Florida Morsani College of MedicineTampaUSA
  4. 4.Departments of Cutaneous Oncology and Sarcoma OncologyMoffitt Cancer CenterTampaUSA
  5. 5.Pediatric Cancer and Blood Disorders InstituteJohns Hopkins All Children’s HospitalSt PetersburgUSA
  6. 6.Department of Cutaneous OncologyMoffitt Cancer CenterTampaUSA
  7. 7.Departments of Oncologic Sciences and SurgeryUniversity of South Florida Morsani College of MedicineTampaUSA

Personalised recommendations